Arbor Biotechnologies Announces Presentations at 2022 Annual Meeting of the American Society of Gene & Cell Therapy
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced upcoming preclinical data presentations at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 16-19, 2022, in Washington, D.C. The Company was also selected to give an invited talk during a pre-meeting workshop on the future of genetic medicines.
“Leveraging our expertise in metagenomic discovery and protein engineering, we have discovered and built a robust toolbox of novel editing enzymes and effectors that may be tailored to the underlying cause of disease for a wide range of genetic conditions,” said Devyn Smith, Ph.D., CEO, Arbor Biotechnologies. “We are highly encouraged by these early results, which in addition to supporting the versatility of our platform, demonstrate the robust activity, high specificity, and broad capabilities of our genomic tools, extending to both ex vivo and in vivo genetic medicine applications.”
ASGCT Annual Meeting Details
- Growing the CRISPR Toolbox for Genetic Medicines – with invited talk by David Scott, Ph.D., Co-founder, Head of Innovation at Arbor Biotechnologies
- Pre-meeting workshop – Sunday, May 15th at 9:40 a.m. EDT
- Engineered Novel Type-V Nuclease System for Efficient CRISPR Editing Delivered by AAV
- Poster Presentation – Monday, May 16th at 5:30 p.m. – 6:30 p.m. EDT
- Characterization of Type V-K CRISPR-associated Transposases
- Poster Presentation – Tuesday, May 17th at 5:30 p.m. – 6:30 p.m. EDT
- Engineering of CRISPR Cas12i to enable therapeutic genome editing
- Poster Presentation – Tuesday, May 17th at 5:30 p.m. – 6:30 p.m. EDT
- Efficient immune cell editing with engineered CRISPR-Cas12i for ex vivo cell therapy
- Poster Presentation – Wednesday, May 18th at 5:30 p.m. – 6:30 p.m. EDT
All abstracts for the ASGCT Annual Meeting are available on ASGCT’s website.
